Viruses in cancer treatment

Clinical and Translational Oncology

Volumn 15, Issue 3, 2013, Pages 182-188

  Alemany, R ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

Immunotherapy; Oncolytic; Virotherapy; Virus

Indexed keywords

CARBOPLATIN; ONCOLYTIC ADENOVIRUS; ONCOLYTIC VIRUS; PACLITAXEL; PEXASTIMOGENE DEVACIREPVEC; TALIMOGENE LAHERPAREPVEC;

ANTINEOPLASTIC ACTIVITY; CAUSAL ATTRIBUTION; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; FLU LIKE SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES SIMPLEX VIRUS 1; HUMAN; HYPERTRANSAMINASEMIA; HYPOTENSION; LYMPHOCYTOPENIA; MEASLES VIRUS; MELANOMA; NEUTROPENIA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PROSTATE CANCER; REOVIRUS; REVIEW; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS STRAIN;

EID: 84878614614     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0951-7     Document Type: Review

References (28)

1. Javier RT, Butel JS (2008) The history of tumor virology. Cancer Res 68:7693-7706
2. Sinkovics J, Horvath J, Szabo-Szabari M (1994) Human cancer vaccines. Leukemia 8(Suppl 1):S194-S197
3. Kelly E, Russell SJ (2007) History of oncolytic viruses: genesis to genetic engineering. Mol Ther 15:651-659
4. De Pace N (1912) Sulla scomparsa di un enorme cranco vegetante del collo dell′utero senza cura chirurgica. Ginecologia 9:82-89
5. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252:854-856
6. Alemany R, Cascallo M (2009) Oncolytic adenoviruses from the perspective of the immune system. Future Microbiol 4:527-536
7. Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ (2012) Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18:2080-2089
8. Yaacov B, Lazar I, Tayeb S, Frank S, Izhar U, Lotem M, Perlman R, Ben-Yehuda D, Zakay-Rones Z, Panet A (2012) Extracellular matrix constituents interfere with Newcastle disease virus spread in solid tissue and diminish its potential oncolytic activity. J Gen Virol 93:1664-1672
9. Hotte SJ, Lorence RM, Hirte HW, Polawski SR, Bamat MK, O'Neil JD, Roberts MS, Groene WS, Major PP (2007) An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res 13:977-985
10. Lam HY, Yeap SK, Rasoli M, Omar AR, Yusoff K, Suraini AA, Alitheen NB (2011) Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol 2011:718710
11. Galanis E (2010) Therapeutic potential of oncolytic measles virus: promises and challenges. Clin Pharmacol Ther 88:620-625
12. Galanis E, Hartmann LC, Cliby WA, Long HJ, Peethambaram PP, Barrette BA, Kaur JS, Haluska PJ Jr, Aderca I, Zollman PJ, Sloan JA, Keeney G, Atherton PJ, Podratz KC, Dowdy SC, Stanhope CR, Wilson TO, Federspiel MJ, Peng KW, Russell SJ (2010) Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 70:875-882
13. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ (2009) Phase II clinical trial of a granulocyte- macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27:5763-5771
14. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH (2011) Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477:99-102
15. Smith RR, Huebner RJ, Rowe WP, Schatten WF, Thomas LB (1956) Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 9:1211-1218
16. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376
17. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP (2000) A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19:2-12
18. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D (2000) An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 6:1134-1139
19. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G (2006) A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14:107-117
20. Pesonen S, Kangasniemi L, Hemminki A (2011) Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data. Mol Pharm 8:12-28
21. Russell SJ, Peng KW, Bell JC (2012) Oncolytic virotherapy. Nat Biotechnol 30:658-670
22. Ribas A, Chmielowski B, Glaspy JA (2009) Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res 15:7116-7118
23. Ottolino-Perry K, Diallo JS, Lichty BD, Bell JC, McCart JA (2010) Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18:251-263
24. Fang J, Nakamura H, Maeda H (2011) The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 63:136-151
25. Coughlan L, Alba R, Parker AL, Bradshaw AC, McNeish IA, Nicklin SA, Baker AH (2011) Tropism-modification strategies for targeted gene delivery using adenoviral vectors. Viruses 2:2290-2355
26. Choi JW, Lee JS, Kim SW, Yun CO (2012) Evolution of oncolytic adenovirus for cancer treatment. Adv Drug Deliv Rev 64:720-729
27. Melcher A, Parato K, Rooney CM, Bell JC (2011) Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19:1008-1016
28. Akram A, Inman RD (2012) Immunodominance: a pivotal principle in host response to viral infections. Clin Immunol 143:99-115